Jessica Hagen
The company's CEO defended its feature as a wellness tool under the 21st Century Cures Act, combating the FDA’s claim that it qualifies as a regulated medical device.
The feature will be available via new iOS and watchOS updates, one year after the U.S. International Trade Commission banned Apple from selling its Series 9, Series 10 and Ultra 2 watches.
The company will use the funds to expand its technology offerings and nationwide partnerships.
The company will use the funds to open a new headquarters in the Bay Area, scale its reach and platform, and expand its workforce.
The company will use the newly garnered funds to scale its Medical-Grade AI offering.
The company also disclosed that it reached an agreement with most holders of its Series A and Series B warrants to convert those warrants into common stock.
The company says the model excels in healthcare applications, outperforming previous models on real-world clinical tasks and is already being adopted by healthcare companies.
The Microdose GLP-1Rx Program will offer low-dose GLP-1 prescriptions combined with behavioral coaching, clinical monitoring and medication management.
The company began trading on the NYSE in May and saw an increase in its stock price upon the news of its second-quarter earnings.
The acquisition comes just months after Cerebral reached a settlement with the FTC over allegations of deceptive subscription and data-sharing practices.